Vincerx Pharma Hosting Key Opinion Leader Webinar On VIP152 Data Presented At American Society Of Hematology Annual Meeting
Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it will host a key
SVB Leerink Initiates Coverage On Vincerx Pharma with Outperform Rating, Announces Price Target of $24
SVB Leerink analyst Jonathan Chang initiates coverage on Vincerx Pharma (NASDAQ:VINC) with a Outperform rating and announces Price Target of $24.
Laidlaw & Co. Initiates Coverage On Vincerx Pharma with Buy Rating, Announces Price Target of $30
Laidlaw & Co. analyst Yale Jen initiates coverage on Vincerx Pharma (NASDAQ:VINC) with a Buy rating and announces Price Target of $30.
B. Riley Securities Initiates Coverage On Vincerx Pharma with Buy Rating, Announces Price Target of $26
B. Riley Securities analyst Kalpit Patel initiates coverage on Vincerx Pharma (NASDAQ:VINC) with a Buy rating and announces Price Target of $26.
60 Biggest Movers From Yesterday
Gainers
Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value of $2.26 billion.
Chardan Capital Maintains Buy on Vincerx Pharma, Lowers Price Target to $30
Chardan Capital analyst Geulah Livshits maintains Vincerx Pharma (NASDAQ:VINC) with a Buy and lowers the price target from $33 to $30.
Vincerx Pharma Q2 EPS $(0.12)
Vincerx Pharma (NASDAQ:VINC) reported quarterly losses of $(0.12) per share.